Amerikanische Gesellschaft für Hirudotherapie

Chronic Otitis Externa (Investigational Adjunct)

Investigational adjunct for refractory chronic otitis externa; topical antimicrobials, aural toilet, and predisposing-factor management remain evidence-based.

Tier C — InvestigationalInvestigativLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Patienten-Zusammenfassung

Ist dies FDA-zugelassen fuer diese Anwendung?
Not FDA-cleared for chronic otitis externa. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
Welche Evidenz existiert?
Tier C (investigational). No controlled trials. Evidence-based first-line management is otologic examination to identify the cause (eczematous, fungal, bacterial, foreign body, underlying cholesteatoma), aural toilet, topical corticosteroid drops for inflammatory disease, topical antifungal for otomycosis, topical antibiotic-steroid combinations for bacterial disease, and identification and avoidance of triggers (water exposure, cotton swab use, hearing aids).
Hauptrisiken
  • Bleeding from each bite site for 6 to 10 hours after the leech detaches
  • Iron-deficiency anemia from cumulative blood loss across multiple sessions
  • Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
  • Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
  • Permanent Y-shaped bite-mark scars or hyperpigmentation at attachment sites
  • Local pain, bruising, swelling, or itching for 1 to 3 days after each session
  • Periauricular placement near the ear canal carries bleeding and infection risks in already inflamed tissue
  • Aeromonas may add a second pathogen to an already infected ear
  • Bites cannot be placed inside the ear canal — that is unsafe
Wer dies nicht in Betracht ziehen sollte
  • Patients without ENT evaluation to confirm the diagnosis and rule out malignant otitis externa, cholesteatoma, or tumor
  • Patients with active fungal or bacterial infection (need targeted topical therapy)
  • Diabetic or immunocompromised patients with otitis externa (high risk of skull-base osteomyelitis)
  • Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, heparin, or daily aspirin used for medical reasons
  • People with hemophilia or any other inherited bleeding disorder
  • Patients with severe anemia (hemoglobin under 10 g/dL)
  • People with an active infection at the planned application site
Was Sie Ihren Kliniker fragen sollten
  • Has ENT evaluated my ear canal and ruled out malignant otitis externa or other serious causes?
  • Have appropriate topical antibiotic, antifungal, or steroid drops been tried?
  • Have aural toileting and trigger avoidance been addressed?
  • What is the published evidence base for leeches in otitis externa?
  • Where exactly will leeches be placed, and how is proximity to the ear canal managed?
  • How will worsening infection be detected during the course?
Wann dringende medizinische Versorgung suchen
  • Bleeding from a bite site that soaks through more than one dressing per hour
  • Bleeding that continues more than 24 hours after the leech detached
  • Spreading redness, warmth, swelling, pus, or red streaks around any bite site
  • Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
  • Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
  • Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
  • Severe ear pain disproportionate to physical findings (possible malignant otitis externa, especially in diabetics)
  • Facial weakness, severe headache, or fever (could indicate skull-base osteomyelitis)
  • New hearing loss, vertigo, or persistent discharge

Was dies NICHT bedeutet

  • It does not mean leech therapy is FDA-cleared for otitis externa — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
  • It does not replace targeted antibiotic, antifungal, or steroid topical therapy.
  • It does not exclude malignant otitis externa, cholesteatoma, or ear canal tumor.
  • It does not address triggers (water, cotton swabs, hearing aids).
  • It does not have controlled-trial evidence and adds risks in an already inflamed area.

Clinical Profile

Category
ent
ICD-10
H60.60, H60.61, H60.62, H60.63
Safety tier
high

Evidence Summary

Chronic otitis externa is inflammation of the external ear canal lasting beyond 6 weeks, often with bacterial (Pseudomonas, Staphylococcus) or fungal (Aspergillus, Candida) component. Evidence-based management includes microscopic aural toilet, topical antimicrobial drops (fluoroquinolone-corticosteroid combinations for bacterial, antifungal for fungal), wick placement in canal-stenotic cases, and addressing predisposing factors (water exposure, dermatitis of the canal, cerumen pathology, hearing-aid use). Necrotizing otitis externa in diabetic or immunocompromised patients is a surgical emergency. No published controlled trials of hirudotherapy exist for chronic otitis externa. The external auditory canal is anatomically inaccessible and high-risk; the periauricular region carries facial nerve and arterial risk.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • Active bacterial or fungal otitis externa
  • Necrotizing (malignant) otitis externa — surgical emergency
  • Tympanic membrane perforation
  • Ear canal placement
  • Cholesteatoma or other middle-ear pathology
  • Hearing aid in situ on affected side

Related Conditions

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.

Chronic Otitis Externa (Investigational Adjunct) — Hirudotherapy Evidence | ASH